Spark Therapeutics doses first Pompe disease patient in study of experimental gene therapy
February 01, 2021 at 11:02 AM EST
The company wants to enroll up to 20 patients with the rare, inherited disease for the study.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|